Novo Nordisk CFO discusses 36 surge in sales driven by Wegovy and Ozempic

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=cgHXanGchXY

Pharmaceutical giant Novo Nordisk (NVO) reported a 36% surge in sales thanks to high demand for weight loss drugs Wegovy and Ozempic. Novo Nordisk CFO Karsten Munk Knudsen joins Yahoo Finance Senior Health Reporter Anjalee Khemlani to discuss the company’s results and what it has in store in the coming months. • Knudsen is “very happy” with the results and the direction the company is heading. Speaking to demand, Knudsen states the company plans to “continue the amazing growth,” citing an increase of supply of starter does for Wegovy, despite shortage of follow up doses. • Knudsen says that to meet increasing demand the company will “expand our industrial footprint.” With increasing competition for weight loss drugs, Knudsen says “This is less about competition head-to-head in a well-defined market. This is really about market expansion.” With increased capital, Knudsen states that the company will “continue to innovate” long term. • About Yahoo Finance: • Yahoo Finance provides free stock ticker data, up-to-date news, portfolio management resources, comprehensive market data, advanced tools, and more information to help you manage your financial life. • Get the latest news and data at finance.yahoo.com • Download the Yahoo Finance app on Apple (https://apple.co/3Rten0R) or Android (https://bit.ly/3t8UnXO) • Follow Yahoo Finance on social: • X: / yahoofinance • Instagram: https://www.instagram.com/yahoofinanc... • TikTok: https://www.tiktok.com/@yahoofinance?... • Facebook: / yahoofinance • LinkedIn: / yahoo-finance

#############################

New on site